CECI, Francesco
 Distribuzione geografica
Continente #
NA - Nord America 1.495
EU - Europa 860
AS - Asia 426
SA - Sud America 8
AF - Africa 6
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.801
Nazione #
US - Stati Uniti d'America 1.480
IE - Irlanda 326
CN - Cina 252
IT - Italia 205
SE - Svezia 112
VN - Vietnam 87
UA - Ucraina 40
DE - Germania 35
FR - Francia 25
GB - Regno Unito 22
HK - Hong Kong 22
RU - Federazione Russa 17
CA - Canada 14
KR - Corea 14
NL - Olanda 14
IN - India 12
BE - Belgio 10
BY - Bielorussia 10
SG - Singapore 10
DK - Danimarca 7
ES - Italia 7
UZ - Uzbekistan 6
CZ - Repubblica Ceca 5
JP - Giappone 5
NO - Norvegia 5
AU - Australia 4
CH - Svizzera 4
IR - Iran 4
PH - Filippine 4
PL - Polonia 4
TR - Turchia 4
BG - Bulgaria 3
FI - Finlandia 3
NG - Nigeria 3
BR - Brasile 2
ID - Indonesia 2
PE - Perù 2
RO - Romania 2
AL - Albania 1
AR - Argentina 1
AT - Austria 1
CL - Cile 1
CO - Colombia 1
EC - Ecuador 1
EU - Europa 1
FJ - Figi 1
GR - Grecia 1
IL - Israele 1
LK - Sri Lanka 1
MU - Mauritius 1
MX - Messico 1
PT - Portogallo 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TZ - Tanzania 1
ZA - Sudafrica 1
Totale 2.801
Città #
Dublin 323
Chandler 278
Beijing 141
Princeton 100
Medford 81
Dong Ket 71
Jacksonville 71
Boston 70
Nyköping 60
Ashburn 54
Wilmington 54
Fairfield 48
Torino 48
Houston 37
Dearborn 34
Ann Arbor 31
Hangzhou 31
Turin 20
Cambridge 19
Central District 19
Encino 19
Woodbridge 18
Norwalk 16
San Mateo 14
Seattle 14
Toronto 13
Seoul 12
Nanjing 11
Brussels 10
Leander 10
Milan 9
Dronten 8
Hebei 8
Hefei 8
Delhi 7
Chengdu 6
Guangzhou 6
Guiyang 6
Philadelphia 6
Redwood City 6
Washington 6
Cologne 5
New York 5
Paris 5
Redmond 5
Salt Lake City 5
Edinburgh 4
Frankfurt am Main 4
Kunming 4
Nanchang 4
Bologna 3
Condat-sur-Vienne 3
Jesolo 3
Mountain View 3
Oslo 3
Pune 3
Rio Saliceto 3
Roskilde 3
Shanghai 3
Singapore 3
Sofia 3
Warsaw 3
Abuja 2
Amsterdam 2
Atlanta 2
Boardman 2
Carate Brianza 2
Cesena 2
Changsha 2
Chelyabinsk 2
Essen 2
Fremont 2
Helsinki 2
Jinan 2
Kagoya 2
Lima 2
London 2
Marseille 2
Montepulciano 2
Pisa 2
Pomezia 2
Reggio Nell'emilia 2
Rieti 2
Rockville 2
Rome 2
Rovigo 2
San Diego 2
San Giorgio A Cremano 2
Silver Spring 2
Upper Marlboro 2
Xi'an 2
Zhengzhou 2
Zoetermeer 2
Aarhus 1
Alba 1
Almada 1
Amersfoort 1
Ballymoney 1
Bandung 1
Baotou 1
Totale 1.949
Nome #
Comparison of68Ga-PSMA-11 PET/CT and18F-Fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence 152
18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival 106
18F-Fluorodeoxyglucose Uptake in Patient With Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (Coronavirus Disease 2019) Referred to Positron Emission Tomography/Computed Tomography for NSCLC Restaging 92
68Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapy 85
[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial 66
(11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. 60
11C- or 18F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer 57
68Ga–Prostate-Specific Membrane Antigen 11 PET/CT Detects Residual Glioblastoma After Radical Surgery in a Patient With Synchronous Recurrent Prostate Cancer 56
11C-Choline PET/CT in patients with biochemical relapse after radical prostatectomy and PSA levels < 0.5 ng/mL 55
18f-fdg pet/ct for restaging gastric cancer after surgical resection 53
COVID-19 and Aspiration Pneumonia: Similar Pulmonary Findings with Different Diagnoses-a Pitfall in [18F]FDG PET/CT 48
11C-Choline PET/CT Identifies Osteoblastic and Osteolytic Lesions in Patients with Metastatic Prostate Cancer 47
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 47
Impact of segmentation and discretization on radiomic features in 68Ga-DOTA-TOC PET/CT images of neuroendocrine tumor 47
11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT 46
11C-Choline PET/CT in hormonal resistant patients after radical prostatectomy 46
European Association of Nuclear Medicine October 22 - 30, 2020 Virtual 46
18F-FLT PET/CT in patients with advanced Non-Small Lung Cancer (NSCLC) treated with Nivolumab: preliminary results 45
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial 45
(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? 43
Event-free survival after 68 Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapy 43
11C-Choline PET/CT and Bladder Cancer: Lymph Node Metastasis Assessment With Pathological Specimens as Reference Standard 42
11C-choline PET/CT scan in patients with prostate cancer treated with intermittent ADT: A sequential PET/CT study 42
LBA02-05 ACCURACY OF 68GA-PSMA-11 FOR PELVIC NODAL METASTASIS DETECTION PRIOR TO RADICAL PROSTATECTOMY AND PELVIC LYMPH NODE DISSECTION 42
Diagnostic Value of Conventional PET Parameters and Radiomic Features Extracted from 18F-FDG-PET/CT for Histologic Subtype Classification and Characterization of Lung Neuroendocrine Neoplasms 40
Predictive accuracy and clinical benefit of a nomogram aimed to predict 68Ga-PSMA PET/CT positivity in patients with prostate cancer recurrence and PSA < 1 ng/ml external validation on a single institution database 39
11C-Choline PET/CT for Restaging of Bladder Cancer 38
11C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel 38
Accuracy of 68Ga-PSMA-11 for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: A multicenter prospective phase III imaging study 38
Ga-68-PSMA PET/CT for early restaging prostate cancer. Preliminary results of a prospective trial in patients with biochemical failure after radical therapy and PSA levels< 2 ng/mL 36
11C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series 36
Clinical application of Fluciclovine PET, choline PET and gastrin-releasing polypeptide receptor (bombesin) targeting PET in prostate cancer 35
(68)Ga-PSMA-PET/CT-Guided Salvage Retroperitoneal Lymph Node Dissection for Disease Relapse After Radical Prostatectomy for Prostate Cancer 34
Aetna and 68 Ga-DOTATATE: A Sequel to "The Injustice of Being Judged by the Errors of Others" 32
What is the best PET target for early biochemical recurrence of prostate cancer?–Authors’ reply 30
Prospective head-to-head comparative phase 3 study between 18F-fluciclovine and 68Ga-PSMA-11 PET/CT in patients with early biochemical recurrence of prostate cancer 30
Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review 30
Predictive value of baseline [18f]fdg pet/ct for response to systemic therapy in patients with advanced melanoma 30
Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial 29
Detection of sarcomatoid lung metastasis with 68GA-PSMA PET/CT in a patient with prostate cancer 27
Choline PET/CT features to predict survival outcome in high risk prostate cancer restaging: a preliminary machine-learning radiomics study 27
Focal Therapy for Prostate Cancer: Complications and Their Treatment 27
Detection of liver lesions during 11C-Choline PET/CT in relapsing prostate cancer patients 26
PET imaging in prostate cancer, state of the art: a review of 18F-choline and 11C-choline PET/CT applications 26
68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy 25
68Ga-PSMA PET/CT in prostate cancer 25
Clinical impact of 11C-Choline PET/CT in recurrent prostate cancer patients after radical therapy: Which is the real impact on treatment decisions? 25
Response Evaluation to Radium-223-Dichloride in Castration-Resistant Metastatic Prostate Cancer using 11C-choline PET/CT and Bone Scintigraphy 25
State of the art of PET/CT with 11-choline and 18F-fluorocholine in the diagnosis and follow-up of localized and locally advanced prostate cancer 24
Prediction nomogram for 68Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer 23
PET/Computed Tomography in the Individualization of Treatment of Prostate Cancer 22
State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer 22
Can we consider eligible for active surveillance prostate cancer patients with biopsy Gleason 3+4 in only one core? Results of single center study after extensive central revision of histological specimens and mid-term follow-up 22
Current application and future perspectives of PSMA PET imaging in prostate cancer 21
New radiopharmaceutical markers for metabolism and receptor 21
Incidental detection of basaloid thymic carcinoma with 68 Ga-PSMA-11 PET/CT in recurrent prostate cancer patient 21
68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy 21
Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68Ga-PSMA-11 PET/CT 20
The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence 19
Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy? 19
68Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: Impact on salvage radiotherapy planning 19
Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial 18
Future Perspective of the Application of Positron Emission Tomography-Computed Tomography-MR Imaging in Musculoskeletal Disorders 18
The dilemma of localizing disease relapse after radical treatment for prostate cancer: which is the value of the actual imaging techniques? 18
Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions 18
Molecular Imaging and Precision Medicine in Prostate Cancer 17
A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy? 17
New aspects of molecular imaging in prostate cancer 16
PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer 15
Diagnostic Accuracy of 11C-Choline PET/CT in Preoperative Lymph Node Staging of Bladder Cancer: A Systematic Comparison With Contrast-Enhanced CT and Histologic Findings 15
Restaging Clear Cell Renal Carcinoma With 18F-FDG PET/CT 15
The influence of PSA flare in mCRPC patients treated with alpha-emitting radiopharmaceuticals 15
Features and management of men with pN1 cM0 prostate cancer after radical prostatectomy and lymphadenectomy: A systematic review of population-based evidence 15
Radiation Therapy After Radical Prostatectomy: What Has Changed Over Time? 15
Standardisation of PSMA images interpretation: why do we need it? 14
SEM, TEM, and IHC Analysis of the Sinus Node and Its Implications for the Cardiac Conduction System 13
PET/CT in prostate cancer 13
How does 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery? 13
A Rare Case of Epididymal Metastasis After Radical Prostatectomy Detected by 68Ga-PSMA PET/CT 13
Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: how to differentiate local from systemic disease? The urologist point of view 13
Preoperative Staging With 11C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer 13
Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row: Nodal oligorecurrent prostate cancer 13
Reply: Comparison of68Ga-PSMA-11 and18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Prospective trial is on its way 12
The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL 12
Therapy assessment in prostate cancer using choline and PSMA PET/CT 12
Imaging of Prostate Cancer Using 11C-Choline PET/Computed Tomography 12
Male Breast Cancer Detected by 68 Ga-PSMA-11 PET/CT in a Patient With Prostate Cancer With Pelvic Lymph Node Metastasis 12
Lung uptake detected by 68Ga-PSMA-11 PET/CT in prostate cancer patients with SARS-CoV-2: a case series 12
Imaging Cancer-Associated Fibroblasts (CAFs) with FAPi PET 12
Erratum to: Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial 11
Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis 11
Imaging of Prostate Cancer Using 11C-Choline PET/Computed Tomography 11
PSMA-PET/CT imaging in prostate cancer: why and when 11
A new type of prostate cancer imaging. Will64CuCl2PET/CT flourish or vanish? 10
Evaluation of Prostate Cancer with 11C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis 10
Potential impact of 68Ga-PSMA-11 PET/CT on the planning of definitive radiation therapy for prostate cancer 10
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET 10
PET/CT and prostate cancer 9
New radiopharmaceutical Markers for Matebolism and receptor 9
First case of 18F-FACBC PET/CT-guided salvage radiotherapy for local relapse after radical prostatectomy with negative 11C-Choline PET/CT and multiparametric MRI: New imaging techniques may improve patient selection 9
Totale 2.945
Categoria #
all - tutte 12.788
article - articoli 0
book - libri 0
conference - conferenze 86
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.874


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201926 0 0 0 0 0 0 0 0 0 2 12 12
2019/2020453 4 2 2 21 5 28 93 48 84 57 90 19
2020/2021436 18 19 20 13 18 13 78 37 44 17 46 113
2021/2022669 8 7 26 15 64 29 48 47 27 41 131 226
2022/20231.053 120 65 21 87 68 317 111 69 100 10 68 17
2023/2024280 65 72 16 25 27 33 10 4 7 21 0 0
Totale 2.956